Section
In a phase 2 trial, oral QY201 significantly improved skin outcomes in moderate-to-severe atopic dermatitis with favorable safety, supporting further phase 3 evaluation.
A deep learning model significantly improves lentigo maligna detection and dermatology resident diagnostic accuracy when applied to dermoscopic images of facial pigmented lesions, underscoring AI’s adjunctive role in clinical dermatol
An international expert consensus provides the first pediatric‑specific framework for low‑dose oral minoxidil (LDOM) in children aged 4–11 years: indications, dosing strategies, safety checks, monitoring, contraindications, and long‑term us
Ivarmacitinib, a selective JAK1 inhibitor, demonstrated rapid efficacy and immune remodeling in palmoplantar pustulosis over 12 weeks, with favorable safety and potential biomarkers for response stratification.
The AMETHYST Phase 2 trial demonstrated that litifilimab significantly improves skin symptoms in cutaneous lupus erythematosus with a favorable safety profile, marking a potential new targeted treatment for this challenging condition.
A telehealth intervention improved sun-protective behaviors among children of melanoma survivors but did not sustain reductions in sunburn rates compared to education alone, highlighting the challenge of long-term melanoma prevention in hig
This study demonstrates that long-term, low-dose capecitabine significantly reduces keratinocyte carcinoma surgeries in patients with refractory cutaneous field cancerization and is generally well tolerated, offering a promising therapeutic
Preoperative neutrophil-to-lymphocyte ratio (NLR) predicts poor outcomes in high-risk cutaneous squamous cell carcinoma, offering a cost-effective tool to enhance risk stratification.
Lichen planus is linked to increased risks of oral and genital cancers, with risks correlating to lesion sites. Despite low absolute risks, vigilant cancer surveillance in LP patients is warranted.
This multicenter randomized study confirms that Belotero Intense with lidocaine is a safe and effective hyaluronic acid filler for lip augmentation, showing noninferiority to Restylane Silk and sustained improvement up to 48 weeks.
LABD97 IgG ELISA significantly improves the detection sensitivity for bullous pemphigoid by identifying more patients with circulating autoantibodies compared to traditional BP180 (NC16A) and BP230 ELISAs.
The COMPASS-SCC, developed from a large international cohort, offers improved prognostic accuracy for cutaneous squamous cell carcinoma compared to existing AJCC8 and BWH staging systems, aiding clinical decision-making for metastasis and m
The phase 2 MIRA trial shows sonelokimab, an IL-17A/F-inhibiting nanobody, significantly improves outcomes in moderate-to-severe hidradenitis suppurativa with good tolerability compared to placebo.
This study evaluates wound healing and pain outcomes among PRF, PRGF, collagen-based dressing, and spontaneous healing in standardized palatal defects, revealing minimal added benefit from adjunctive treatments in healthy individuals.
Alopecia areata regrowth may present atypically with acquired curly hair texture, associated with pili torti ultrastructural changes, signifying a unique phenotype requiring clinical recognition.
The Cutaneous Lymphoma International Prognostic Index (CLIPI) enhances risk stratification and predicts progression and treatment response beyond conventional staging in advanced mycosis fungoides and Sézary syndrome.
Systemic relapse after stage I melanoma, though rare, portends higher tumor burden and poorer survival compared with relapse after stage II/III disease, as evidenced by data from 365 metastatic melanoma patients in the Spanish Melanoma Regi
This study presents a comprehensive single-cell RNA-sequencing atlas of CTCL, identifying oncogenic transcriptional programs and immune microenvironment features that offer new therapeutic targets for advanced-stage disease.
A randomized controlled trial demonstrates superior symptom relief with fractional CO2 laser treatment over topical clobetasol in women with vulvar lichen sclerosus, suggesting a novel therapeutic approach.
This study highlights dupilumab’s long-term effectiveness and safety in managing pediatric atopic dermatitis over 3 years, revealing age-related differences in symptom control and treatment persistence.
